drugset / Trial / NCT03478033
Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis
Unknown
230 enrolled
Shanghai Public Health Clinical Center
Chongqing Public Health Medical Center · collabShenzhen Third People's Hospital · collabThe Fourth People's Hospital of Nanning · collabThe Guangxi Zhuang Autonomous Region Longtan hospital · collabYunnan Provincial Infectious Disease Hospital · collabZhejiang University · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
To compared the efficacy and safety of rifampicin and rifabutin which included in the standard treatment of anti-tuberculosis in HIV/AIDs patients combined with pulmonary tuberculosis, a multi-center, prospective cohort will be established. Antiviral efficacy and drug drug interaction will be investigated in order to provide optimized treatment for HIV/AIDs with tuberculosis.
Timeline
- Start
- 2018-04-15
- Primary completion
- 2020-06-01
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifabutin | Small molecule | 150 mg | — |
| Subject | Rifabutin | Small molecule | 0.45 g | — |
| Subject | Rifabutin | Small molecule | 0.6 g | — |
| Comparator | Rifampin | Small molecule | 10 mg/kg | — |
| Comparator | Rifampin | Small molecule | 20 mg/kg | — |
| Comparator | Rifampin | Small molecule | 150 mg | — |